
Azenta (AZTA) Stock Forecast & Price Target
Azenta (AZTA) Analyst Ratings
Bulls say
Azenta is positioned well within the life sciences market, offering a range of solutions for sample management and analysis needs. Despite a revenue and EPS miss for FY26, the company has provided strong guidance with expectations of 3-5% organic revenue growth and +300 bps adjusted EBITDA margin expansion. The company's focus on both Sample Management Solutions and Multiomics segments, as well as potential upside drivers such as M&A and faster outsourcing, support a positive outlook on the company's growth potential.
Bears say
Azenta is facing challenges with weak growth in its Multiomics segment and constrained capital demand for its services, leading to margin deleveraging and missed consensus estimates. While the company has a long-range plan for revenue and margin improvement, execution risk and potential competition could hinder their progress. With a lowered FY26 revenue outlook and an adjusted EBITDA margin that missed consensus, the stock may be facing a bottom as downside risks are limited by the company's balance sheet and FCF profile. However, potential upside drivers, such as a recovery in C&I de-stocking and cross-selling opportunities, could lead to a better performance for the stock in the future.
This aggregate rating is based on analysts' research of Azenta and is not a guaranteed prediction by Public.com or investment advice.
Azenta (AZTA) Analyst Forecast & Price Prediction
Start investing in Azenta (AZTA)
Order type
Buy in
Order amount
Est. shares
0 shares